Credit: Original article published here.In the recently completed CheckMate 817 trial, researchers evaluated flat-dose nivolumab plus weight-adjusted ipilimumab as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC). According to the study’s authors, the nivolumab plus ipilimumab regimen was associated with durable response and manageable safety in the primary cohort of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1. The findings were reported in the Journal for the Immunotherapy of Cancer. In addition, the team reported that nivolumab with ipilimumab showed manageable treatment-related toxicity and a clinically meaningful 3-year overall survival (OS) rate in higher-risk subgroups including patients with ECOG PS 2, ECOG PS 0-1 with untreated brain metastases, renal impairment, hepatic impairment, or controlled HIV infection. Investigators noted these findings were comparable to results from previous phase 3 studies on patients with metastatic NSCLC. Nivolumab Plus Ipilimumab Shows Promise for NSCLC The clinical trial enrolled 391 patients with NSCLC in the primary cohort and 198 patients in the special populations cohort. Both groups received nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg per kg every 6 weeks. The primary end points were grade III-IV and grade V immune-mediated adverse events (AEs)